Patient Enrollments, Innovation Awards, Appointments, and Promotions - Analyst Notes on Endo, St. Jude, Impax, Novavax and PTC Therapeutics

NEW YORK, June 25, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Endo International plc (NASDAQ: ENDP), St. Jude Medical Inc. (NYSE: STJ), Impax Laboratories Inc. (NASDAQ: IPXL), Novavax, Inc. (NYSE: NVAX) and PTC Therapeutics, Inc. (NYSE: PTCT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4082-100free.

--
Endo International plc Analyst Notes
On June 9, 2014, Endo International plc (Endo) announced that its subsidiary, American Medical Systems Inc. (AMS), has enrolled the first patient for Embrace™- AMS's 522 post market surveillance study for the Elevate™ Anterior and Apical Prolapse Repair System. Camille Farhat, President of AMS said, "These studies demonstrate the commitment of AMS to provide medical evidence that further validates the safety and efficacy of our products. As a global leader in Women's Health, we will continue to invest in the science that supports these therapies and maintain our support of robust physician training as well as patient education that encourages conversations about the risks and benefits of these treatments." The Company expects that there will be 494 patients enrolled in the Embrace study at approximately 40 sites throughout the United States. The full analyst notes on Endo are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/ENDP/report.pdf

--
St. Jude Medical Inc. Analyst Notes
On June 18, 2014, St. Jude Medical Inc. (St. Jude) announced that the Nanostim™ leadless pacemaker has been the recipient of the 2014 Innovation Award at Cardiostim 2014 - the 19th World Congress in Cardiac Electrophysiology and Cardiac Techniques. According to the Company, the award recognizes Nanostim leadless pacemaker as the industry's most innovative product in the sector of electrophysiology and cardiac techniques. St. Jude informed that the Nanostim leadless pacemaker is less than 10% the size of a conventional pacemaker and is the least invasive pacing technology on the market today. Eric S. Fain, M.D., Group President of St. Jude Medical said, "St. Jude Medical is honored that our Nanostim pacemaker received this significant recognition from the EP community. We believe that the health benefits associated with this leadless technology will enable physicians who use this device to improve the lives of patients worldwide." The full analyst notes on St. Jude are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/STJ/report.pdf

--
Impax Laboratories Inc. Analyst Notes
On June 20, 2014, Impax Laboratories Inc. (Impax) stock increased 2.5% to end the day at $30.00. The Company's stock increased 5.26% over the past three trading days compared to the Nasdaq Composite which gained 0.71% and to the Dow Jones Industrial Average which rose 0.82% during the same trading period. The full analyst notes on Impax are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/IPXL/report.pdf

--
Novavax, Inc. Analyst Notes
On June 19, 2014, Novavax, Inc. (Novavax) announced managerial promotions within its management team. The Company informed that John A. Herrmann III, J.D. has been named as Senior Vice President, General Counsel and Corporate Secretary and Denis Courbron, M.S., PMP has been appointed as Vice President, Global Program Management to lead Novavax' program management efforts covering all vaccine development programs. Stanley C. Erck, President and CEO said, "I am very pleased to announce the promotions of John and Denise. Their contributions over the last number of years have been critical to the success of the company. John has been irreplaceable assisting the management team and the board to navigate the regulatory, compliance, and corporate governance requirements of a public company. Denise's long history of experience with government contracts and project management has been integral to the successful execution of our contract with HHS BARDA." The full analyst notes on Novavax are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/NVAX/report.pdf

--
PTC Therapeutics, Inc. Analyst Notes
On June 11, 2014, PTC Therapeutics, Inc. (PTC Therapeutics) announced that Ronald C. Renaud, Jr. has been appointed to the Company's Board of Directors. The Company informed that prior to his new role, Mr. Renaud has served as the President and CEO of Idenix Pharmaceuticals, Inc. since October 2010. Stuart W. Peltz, Ph.D., CEO, PTC Therapeutics, Inc., said, "We are delighted to welcome Ron to PTC's Board of Directors. Ron brings tremendous skills and experience to PTC that will be invaluable to our future growth and success. His demonstrated leadership experience in building successful biotechnology companies, his former background as an equity research analyst and his deep knowledge of the life sciences industry will provide valuable contributions to our company." The full analyst notes on PTC Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Jun-25-2014/PTCT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED